Approved on November 20, 2020, it offers a vital treatment option for managing these rare genetic conditions.

Approved on October 14, 2020, it provides a crucial option for managing and treating Ebola virus disease.

Approved on September 4, 2020, pralsetinib (Gavreto) represents a significant advancement in targeted cancer therapy.

Approved on September 3, 2020, Detectnet (copper Cu 64 dotatate) provides a critical tool for the diagnosis and management of NETs.

Approved on August 28, 2020, somapacitan (Sogroya) offers a convenient once-weekly injection, improving adherence and quality of life for patients.

Approved on August 26, 2020, clascoterone (Winlevi) offers a novel mechanism of action by inhibiting androgen receptors in the skin, reducing oil production and inflammation associated with acne.

Approved on August 7, 2020, oliceridine (Olinvyk) is intended for patients who have not found relief with other treatments.

risdiplam FDA approval on August 7, 2020, has provided new hope and convenience for individuals affected by SMA.

tafasitamab FDA approval on July 31, 2020, provides hope for patients with limited treatment options, though ongoing studies are necessary to fully understand its long-term efficacy and safety.

Approved by the FDA on July 24, 2020, it utilizes innovative CAR-T cell technology to target and eliminate cancer cells, although it comes with significant risks and side effects that require careful management by healthcare professionals.

on August 12, 2021, the FDA expanded its approval to include the treatment of idiopathic hypersomnia (IH) in adults.

The U.S. Food and Drug Administration (FDA) approved Inqovi on July 7, 2020, for the treatment of certain types of myelodysplastic syndromes (MDS).